GET DAILY SIGNALSBioMarin (BMRN) Posts Record Revenue but Trims 2026 Guidance
Key Takeaways
- BioMarin reported third-quarter 2026 total revenue of roughly $1.03 billion, up 32% year over year (Y/Y), topping $1 billion in a single quarter for the first time.
- Non-GAAP (adjusted) diluted EPS (earnings per share) came in at $0.23, well above analyst consensus estimates.
- Full-year 2026 revenue guidance was lowered to about $3.85 billion at the midpoint, citing order-timing uncertainty from a single international customer.
- Full-year 2026 non-GAAP EPS guidance was reduced to $2.95 at the midpoint, a cut of roughly 41%.
- Growth was led by the Metabolic Conditions franchise, up 44% Y/Y, while Voxzogo revenue rose 12% Y/Y to $245 million.
- Shares slipped in after-hours trading as investors weighed the milestone revenue against the lowered outlook.
Why This Quarter Carried Extra Weight
BioMarin’s third-quarter report carried unusual weight because it offered the first extended look at the company’s post-acquisition profile. BMRN completed its acquisition of Amicus Therapeutics earlier in 2026, adding Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease) to its rare-disease portfolio. Investors were watching closely to see whether the deal would deliver the promised revenue diversification and cost synergies, and whether Voxzogo’s growth in achondroplasia could keep momentum. With the company crossing the $1 billion quarterly-revenue threshold for the first time, the report confirmed meaningful scale, but a simultaneous reduction in full-year guidance highlighted lingering execution and timing risks heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
BMRN reported third-quarter 2026 total revenue of $1.025 billion, a 32% increase from the same period a year earlier and roughly in line with Wall Street consensus of about $1.02 billion. Non-GAAP diluted EPS was $0.23, which beat analyst expectations.
The Metabolic Conditions franchise was the standout, generating $744 million in revenue, up 44% year over year. Within that segment, Galafold revenue reached $152 million (up 10% Y/Y), while Pombiliti + Opfolda contributed $49 million (up 58% Y/Y). On the skeletal side, Voxzogo revenue grew 12% Y/Y to $245 million, despite a large order shifting from the third quarter into the fourth.
Management updated full-year guidance, lowering the 2026 revenue midpoint to approximately $3.85 billion from $3.9 billion, reflecting uncertainty in the timing of multiple orders from a single international customer. Full-year non-GAAP diluted EPS guidance was reduced to $2.95 at the midpoint, a decrease of roughly 41% from the prior outlook. From what I see, the order shift in Voxzogo was the main driver behind the revised numbers.
Market Reaction and Investor Sentiment
The market’s response reflected a tension between a strong headline quarter and a softer outlook. While the $1 billion revenue milestone and the EPS beat underscored BMRN’s growing scale, the reduced full-year guidance tempered enthusiasm. Shares declined roughly 4% to 5% in after-hours trading following the announcement. The cut in adjusted EPS guidance—down about 41% at the midpoint—appeared to weigh most heavily on sentiment, as investors reassessed near-term profitability expectations. The order-timing uncertainty flagged in the Voxzogo and metabolic franchises also raised questions about quarterly revenue volatility, even as underlying patient demand remained solid.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several developments closely. First, the timing and magnitude of the deferred Voxzogo orders, particularly the large international order expected in the fourth quarter, will shape near-term revenue trends. Management noted that more than 75% of Voxzogo revenue now comes from outside the U.S., which increases exposure to order-timing swings.
Second, the integration of the Amicus portfolio remains a central theme. Cost synergies and the continued ramp of Galafold and Pombiliti + Opfolda will be key to whether the acquisition becomes accretive to earnings as management targets for 2027.
Third, pipeline catalysts could influence the narrative. Management pointed to the potential launch of Voxzogo in hypochondroplasia as a meaningful growth opportunity, along with a newly added investigational Fabry disease therapy that could become the first subcutaneous enzyme treatment for the condition.
Finally, margin trends and operating leverage will matter. With adjusted operating margins under pressure relative to historical levels, investors will be monitoring whether scale and integration efficiencies can restore profitability over time.
My Take on Using Tickeron Tools
In my own research, I often rely on Tickeron’s AI Screener to quickly surface comparable names and technical setups across the biotech space. It lets me apply customizable filters for industry, market cap, and AI signals without spending hours on manual work. The tool has become a regular part of how I cross-check ideas like the one presented by BMRN this quarter.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BMRN turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Oscillator exited the oversold zone, 18 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on BMRN as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 162 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 65 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
BMRN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.749) is normal, around the industry mean (2.904). BMRN's P/E Ratio (154.405) is considerably higher than the industry average of (-0.738). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of innovative pharmaceuticals for serious diseases & medical conditions
Industry Biotechnology